UNSPSC 51411503: Fenetradil

This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9GXY5Z0873. European Medicines Agency schedules Fenetradil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07559MIG. Fenetradil generally arises in the molecular formula C22H36N2O3.

UNSPSC 51411503 Fenetradil, a Commodity code, describes pharmaceutical active pharmaceutical ingredients and finished medications procured by state and local health agencies, fire rescue departments, and cooperative purchasing alliances for emergency medical services, pharmacy benefit programs, and institutional healthcare delivery. State and local governments buy specific finished medications under this code—emergency life support drugs like epinephrine, labetalol, adenosine, and diltiazem for paramedic protocols; generic multi-source pharmaceuticals for state employee health plans and Medicaid programs; and over-the-counter products for institutional dispensing. Issuing bodies include city fire and rescue departments, state health and human services commissions, and cooperative purchasing organizations serving multiple jurisdictions. The City of Tampa's Fire Rescue and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the mix of direct municipal procurement and interstate cooperative vehicles that dominate this code's activity.

Recent opportunities span Florida and Minnesota, with broader multistate reach through cooperative purchasing. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications to supply Tampa Fire Rescue with 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials, with bids due April 8, 2026, and an estimated contract value of $40,000.00 including a 5 percent Small Local Business Enterprise bid discount. The Minnesota Department of Administration issued an RFP through MMCAP on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across Minnesota and Oregon, with proposals due March 26, 2026, requiring vendors to maintain relationships with AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co. The Texas Health and Human Services Commission issued an RFI (No. HHS0017013) posted April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs, indicating exploratory procurement activity in a third state.